The EU did a Brexit trade deal with the pharma industry: it tried to lock in a perceived short-term price advantage at the expense of everything else. Instead of prioritising the speed and security of supplies at any price, the EU prioritised the price. The EU paid 24% less for the Pfizer vaccine than the US, for example. For the Oxford/AstraZeneca vaccine, the price gap is 45%. The UK almost certainly paid a lot more. It is no wonder that the manufacturers are prioritising orders on a first-come, first-serve basis, and from countries that pay the full price. The price difference is macroeconomically irrelevant. But if vaccine shortages lead to longer lockdowns, the indirect effect of that short-sighted policy will be massive.
Related Articles
L20 STATEMENT TO THE G20 LEADERS’ SUMMIT
November 17, 2020
Mathew D. Rose
Economics, Finance, Green New Deal, Inequality, Neo-Liberalism in the EU, Tax
0
There can be no returning to what was called “normality”, which is more a state of insanity destroying society and the planet Read here
Bill Mitchell: A progressive European superstate will never come to pass
“A progressive European superstate will never come to pass” Read here
Carlo Martuscelli – Europe’s manufacturing slump shows no signs of ending
‘The eurozone manufacturing PMI fell to 45.6, a seven-month low, from 45.8, disappointing expectations for a modest increase to 46.0. In Germany the indicator came in at 42.6, a three-month low, while in France it fell for a second straight month […]
Be the first to comment